2024-03-19 09:36:55 ET
Summary
- Ocugen Inc. is a biotechnology company focused on gene and cell therapies and inhalable vaccine development.
- Their OCU400 program, targeting inherited eye diseases, is progressing to phase 3 clinical trials in 2024.
- The company's participation in a $5 billion NIAID-funded trial for an inhaled COVID-19 vaccine enhances its financial and strategic position.
- Funding concerns loom with a cash runway of under a year, necessitating further capital infusion to continue R&D.
- Despite risks, Ocugen's promising pipeline, particularly OCU400, positions it as a speculative "buy" with substantial upside.
...
Read the full article on Seeking Alpha
For further details see:
Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues